Calviri
Tempe · Founded 2015
About Calviri
Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform. On its course to eradicate cancer it develops new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting. The company's approach can provide both cancer diagnostics and vaccines. It is based on the discovery of an unrecognized source of frameshift neoantigens. These immunogenic peptides are generated from very frequent errors in tumor-cell RNA synthesis and processing. They provide both cancer-specific and shared frameshift neoantigens for a new class of diagnostic and vaccine products. Calviri was founded in 2018 and is headquartered in Tempe, Arizona.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $16.6M
- Last round: Undisclosed (Nov 2024)
- Website: https://calviri.com
- Phone: +1 480-205-6436
Industries & Categories
Biotechnology, Health Diagnostics, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/calviri-173375 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.